CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 13 enrolled
Drug / intervention
[11C] desmethyl-loperamide +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01668147
NCT01668147Phase 2Completed
CompareCT.gov

Influence of Efavirenz and Ritonavir on Human Brain P-Glycoprotein Activity Using PET Imaging

Washington University School of Medicine·interventional·Posted Aug 17, 2012·Updated Jan 22, 2020

In Brief

A Phase 2 clinical trial evaluating [11C] desmethyl-loperamide, Control - no pretreatment, and 2 other interventions for Drug Effects. Completed, enrolled 13 participants across 1 site.

Detailed Summary

To determine the effects of ritonavir and efavirenz on the activity of P-glycoprotein in human brain.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDrug Effects
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 17, 2012
Enrollment StartAug 1, 2012
Primary CompletionJun 1, 2016
Study CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 13.9 years ago

Interventions

[11C] desmethyl-loperamidedrug

IV administration of 10-14 mCi of \[11C\] desmethyl-loperamide with PET/CT imaging

Control - no pretreatmentother

Session 1: IV administration of 10-14 mCi \[11C\] desmethyl-loperamide (dLop) with PET/CT imaging and brain MRI

Oral ritonavirdrug

Session 2: Pretreatment with oral ritonavir for 3 days followed by IV administration of 10-14 mCi \[11C\]dLop with PET/CT imaging and brain MRI

Oral efavirenzdrug

Session 3: Pretreatment with oral efavirenz for 14 days followed by IV administration of 10-14 mCi \[11C\]dLop with PET/CT imaging and brain MRI